OPT TL3
Alternative Names: OPT-TL3Latest Information Update: 19 Mar 2004
At a glance
- Originator Optimer Pharmaceuticals
- Class Antivirals
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 19 Mar 2004 Discontinued - Preclinical for HIV infections treatment in USA (unspecified route)
- 31 Dec 2002 Preclinical trials in HIV infections treatment in USA (unspecified route)